Special feature: Top 10 clinical trial mistakes
14 October, 2009 by Staff WritersHere are 10 common clinical trial mistakes you should avoid.
Australian biotech market watch 09/10/09
09 October, 2009 by Tim DeanCSL, Primary Health Care, Cochlear, Blackmores, Ansell
Australian biotech market watch 07/10/09
07 October, 2009 by Tim DeanRamsay, Cochlear, pSivida, Ansell, Biota
Australian biotech market watch 02/10/09
02 October, 2009 by Tim DeanBiota, Ramsay, Cochlear, Blackmores, Clinuvel
CSL speaks out on vaccination 'myths'
01 October, 2009 by Tim DeanMyth busting panel dispels 'myths' surrounding the H1N1 swine flu vaccine.
Australian biotech market watch 30/09/09
30 September, 2009 by Staff WritersCochlear, Ansell, pSivida, Fisher & Paykel, Sonic Healthcare
Australian biotech market watch 28/09/09
28 September, 2009 by Staff WritersClinuvel Pharmaceuticals, Cellistis Limited, Acrux, CSL Limited
Bionomics in the money
08 September, 2009 by Tim Dean$15 million capital raising enough to fund trials for over two years.
Prima gets go ahead for ovarian cancer vaccine trial in US
02 September, 2009 by Tim DeanFDA gives clearance for Phase IIb trial of CVac vaccine in the US.
Sirtex profits up eightfold
28 August, 2009 by Tim DeanGains made through increased sales and currency movements.
Australian biotech market watch 28/08/09
28 August, 2009 by Tim DeanSonic, Sirtex, Blackmores, Healthscope, Cellestis
A better test to detect DNA
28 August, 2009 by Staff WritersApplications in diagnosing diease and investigating crimes.
Cellestis posts strong result
26 August, 2009 by Tim DeanFinancial year 2009 results are in showing record sales and profits.
New Sigma-Aldrich lab offers knockout rat models
24 August, 2009 by Staff WritersCompoZr Zinc Finger Nuclease technology enables creation of next-generation rodent research models that can provide new insight into human disease.
CSL's ups and downs
20 August, 2009 by Tim DeanCSL had it's share of ups and downs last year, but overall it's coming out on top.
